Search
Displaying all 2 results
Lunsotogene parvec
go.drugbank.com/drugs/DB18278
ApprovedInvestigational
Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. It acts by delivering functional copies of the human OTOF gene specifically to inner hair cells via an engineered hair-cell-s...
Otoferlin Gene-mediated Hearing Loss
go.drugbank.com/conditions/DBCOND0170571Drugs: Lunsotogene parvec